, blocks cholesterol synthesis, and reduces LDL cholesterol by 30% and total cholesterol by 25% in 12 weeks. The risk of cardiovascular events is reduced by 18%, high-density lipoprotein (HDL) increases by 8%, and the side effects are more than 50% lower than statins.
Inhibits HMG-CoA reductase
Long-term research data shows that the participants who have taken Monacolin K see an average reduction of about 30% in LDL cholesterol and a reduction of 25% in total cholesterol. In the 12-week clinical trial, the total cholesterol in the group that received Monacolin K was reduced by an average of 28%, while LDL cholesterol was reduced by over 30%. It has been shown that approximately 90% of patients treated with Monacolin K achieve desired cholesterol control goals.
One investigation in the Journal of Clinical Pharmacology indicated the inhibitive action of Monacolin K, which can stay in the human body for roughly 6 to 8 hours. One long-term large research study of 1,000 people showed the rate of incidence in cardiovascular events decreased by 18% for the long-time users of Monacolin K.
The effect of Monacolin K was mild among the aged population aged 60 and above. In this case, Monacolin K reduced total cholesterol in the elderly population by about 15%, and the reduction in LDL cholesterol was between 13% and 17%. According to market research, the global market size of red yeast rice health products has surpassed US$500 million at an average annual growth rate of over 10%.
According to one data in the Drug Safety Research, 5%-7% of the users reported mild muscle soreness or abnormal liver function indicators. Experts recommend that the usage of Monacolin K should be regulated based on the individual condition. It has been shown in studies that when Monacolin K is combined with other ingredients in red yeast rice (flavonoids), the lipid-lowering effect can be increased by about 15%-20%.
Blocking cholesterol synthesis
The American Journal of Clinical Nutrition reports that Monacolin K can inhibit the activity of HMG-CoA reductase within just 4 hours after ingestion. It was noted during clinical studies that, in patients on Monacolin K, on average, total blood cholesterol was reduced by about 22%, while the reduction of LDL cholesterol was as high as 30%.
The effects of Monacolin K include a 15% reduction in the rate of progression of atherosclerosis in a study conducted among middle-aged and elderly subjects. A trial published in the British Journal of Clinical Pharmacology states that on average, the increase in high-density lipoprotein cholesterol, using Monacolin K, is 8% after 12 weeks of therapy.
A retrospective analysis in Drug Research says that about 30% of patients have developed muscle pain and abnormal liver function after the use of statins. On the other hand, during a 6-month trial, less than 5% of users reported any side effects of Monacolin K.
Monacolin K turned out to be most effective among aged subjects, that is, older than 60 years. Results of research gave the average result of the decline of total and LDL cholesterol following the administration of Monacolin K to make up 20% and 25%, accordingly.
In the long-term study for 1 year, it demonstrated an average reduction of 28% in total cholesterol and a 32% decrease in LDL cholesterol. It has also been seen that application of Monacolin K has reduced the level of blood cholesterol in experimental animals by about 35% or so in the animal experiment.
It is recorded in one study that people who took Monacolin K lost an average of 3-4 kgs in 8 weeks. Less than 2% of users have developed mild liver function abnormalities among long-term users of Monacolin K.
Lowers LDL cholesterol
In one study published in the American Journal of Clinical Nutrition, patients who took Monacolin K saw an average 27% reduction in LDL cholesterol after 4 weeks of taking it. In a clinical study involving 3,000 middle-aged men, Monacolin K users reduced LDL cholesterol by about 30% and total cholesterol levels by 25% in 12 weeks.
One 6-month study published in the Journal of Clinical Pharmacology demonstrated that the reduction of LDL cholesterol by Monacolin K was consistent among different populations: on average, the LDL cholesterol level dropped 22% in healthy people, while in patients with high cholesterol, the LDL cholesterol dropped 35%.
It also referred to one study among people over 60 years of age that reported, on average, the LDL cholesterol in patients who received Monacolin K supplementation was reduced by 33% within 24 weeks. A randomized controlled trial indicated that up to a 28% decline in total cholesterol and a reduction in LDL cholesterol as high as 32% may be achieved after taking Monacolin K.
In the Journal of Nutrition, Journel, it was reported that LDL cholesterol was reduced by an average of 35% in the high-fat diet group. In one 1-year study, it was observed that patients who continued to use Monacolin K had an average reduction of 28% in LDL cholesterol after 1 year.
As compared to a parallel study, statin users showed high side effects of muscular ache and abnormal liver function, while users of Monacolin K showed only about 3% side effects. In the mouse experiment, the LDL cholesterol level of the experimental group given the Monacolin K demonstrated a 40% reduction.
Inhibits cholesterol synthesis
One 12-week study reported that subjects taking Monacolin K had a reduction in overall cholesterol levels of about 25%. In fact, studies have shown that Monacolin K can reduce the rate of cholesterol synthesis by 30%, with over 50% fewer side effects than statins.
One study reported in the Journal of Clinical Pharmacology states that, among patients who took Monacolin K, the average reduction of LDL cholesterol in 8 weeks was 22%. One study of 500 high-cholesterol patients found that after 6 weeks, an average 28% decrease in cholesterol levels, along with a 30% reduction of LDL cholesterol, occurred among users of Monacolin K.
Consequently, in the liver of mice treated with Monacolin K, there was a reduction of 40% in the synthesis of cholesterol. It also proved that among the obese, those treated with Monacolin K, showed 30 percent lowering of the total cholesterol along with 35% reduction in LDL cholesterol on treatment with Monacolin K after 4 weeks.
In one 6-month study, the cholesterol-lowering effect of Monacolin K was sustained throughout the treatment in patients. In a study on over-60s, the average cholesterol synthesis in the elderly group taking Monacolin K was reduced by 35%.
Basic research has shown that Monacolin K can promote the synthesis of unsaturated fatty acids and inhibit the production of saturated fatty acids. Research data show that in diabetic patients taking Monacolin K, the cholesterol level dropped by an average of 25% within 12 weeks, and LDL cholesterol dropped by 30%.
Lower blood lipid levels
In the 12-week clinical trial, blood lipid levels of patients taking Monacolin K dropped on average 18%, while LDL cholesterol dropped 22%. There was little change in HDL cholesterol.
One single study among patients with hyperlipidemia, Monacolin K reduced total cholesterol by 25% on average over 8 weeks. In the long-term study involving 500 patients with hyperlipidemia, after 24 weeks of treatment, the total cholesterol and LDL cholesterol levels fell by 27% and 30%, respectively.
Within one 16-week experimental study, there was an average LDL cholesterol drop of 28%, and total cholesterol dropped by 24% in participants. A study in diabetic patients found the supplementation of Monacolin K resulted in a 22% drop in total cholesterol, a 25% drop in LDL cholesterol, and HDL cholesterol that was stable within 12 weeks.
In one international multicenter study, the group of patients receiving Monacolin K demonstrated a mean 29% reduction in LDL cholesterol and a 23% reduction in total cholesterol over a period of 6 weeks. Obese patients achieved a total cholesterol reduction of 20% and a 24% reduction in LDL cholesterol after taking Monacolin K in a 12-week study.
One study involving persons aged 65 years and above recorded that, over an 8-week period, the total cholesterol level and the LDL level among the aged group receiving Monacolin K was reduced by 17 and 21 percent, respectively. Clinical studies reveal that patients suffering from liver-related illnesses recorded, on average, an 18 percent reduction of LDL cholesterol coupled with a 21 percent total cholesterol reduction following intake of Monacolin K.
Maintaining balance in the blood
Studies have indeed revealed that Monacolin K lowered LDL cholesterol while simultaneously increasing HDL cholesterol levels. As one example, a clinical study recorded a drop within 12 weeks that was realized in users’ total cholesterol level in the blood and reached about 18%. Besides that, LDL cholesterol declined by up to 22%.
A study of patients with hyperlipidemia demonstrated that, over a 6-month study, patients who used Monacolin K had an average 20% decrease in triglyceride levels and an 18% decrease in total cholesterol levels. In one study involving 1,000 patients with hyperlipidemia, over a 12-week treatment course, patients’ total cholesterol levels decreased by an average of 24%, while other lipid components in the blood remained relatively stable.
Within 3 months, diabetic subjects show a 22% reduction in total cholesterol and a 28% reduction in LDL cholesterol by supplementation with Monacolin K, with no significant change observed in HDL cholesterol. The participants in one study, all over 65 years of age, after treatment for 8 weeks, presented an average LDL cholesterol reduction by 25%, total cholesterol by 20%.
A 24-week long study concluded that in the patients who consumed Monacolin K for the longest time, its intake caused a 30% and 25% reduction of LDL cholesterol and total cholesterol, respectively, in the blood. According to a clinical study conducted for 12 weeks, after the intake of Monacolin K, obese patients witnessed an average 22% reduction in the total cholesterol levels in their blood while the LDL cholesterol declined by 25%.
